REGENERON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 901.2 USD | +0.79% |
|
-3.74% | +2.61% |
| Apr. 17 | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
| Apr. 17 | The market is pinning its hopes on earnings reports |  |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
901.2
USD
Average target price
1,036
USD
Spread / Average Target
+14.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.61% | 96.84B | |
| -3.39% | 102B | |
| -1.46% | 21.48B | |
| -18.14% | 20.82B | |
| -7.40% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B | |
| -18.85% | 8.88B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Says Linvoseltamab Shows 71% Objective Response Rate in Multiple Myeloma Phase 2 Trial Expansion Dose Group
